中文摘要：

目的：评价氨氯地平联合替米沙坦改善高血压合并糖尿病患者微蛋白尿的疗效。方法： 计算机检索OVID-LWW、CNKI和万方数据库，收集以氨氯地平联合替米沙坦为干预措施改善高血压合并糖尿病 24 h微量尿蛋白含量的随机对照试验研究（RCT）。评价纳入研究进行方法学质量，提取有效数据进行Meta分析。结果： 共纳入5个RCT，共450例高血压合并糖尿病患者。试验组采用氨氯地平联合替米沙坦治疗，对照组采用单纯替米沙坦治疗，Meta分析结果显示，治疗前，治疗前两组 24 h微量蛋白尿含量比较差异无统计学意义（P＞0.05）。治疗后，两组24 h 微量蛋白尿含量差异有统计学意义（P＜0.05）。结论：氨氯地平联合替米沙坦为干预措施改善高血压合并糖尿病24 h微量尿蛋白含量效果良好。但因纳入文献的试验方法学质量较低，仍需大样本、长期不良反应随访。

英文摘要：

AIM： To evaluate the efficacy of amlodipine plus telmisartan in improving mi- croalbuminuria of subjects with hypertension and diabetes. METHODS： Electronic databases of OVID-LWW, CNKI and Wanfang were searched to collect randomized controlled trials （RCT） by interventions of amlodipine plus telm-isartan in improving microalbuminuria of sub- jects with hypertension and diabetes, the meth-odological quality of the trials and extracted val-id data for Meta-analysis was evaluated. RE-SULTS.5 RCT and 500 patients were included. Test group were treated by amlodipine plus telmisartan, the control group were treated by telmisartan. Meta analysis showed that no sta-tistically significant was found for 24 h mi- croalbuminuria between two groups before treat-ment, but statistically significant was found af- ter treatment. CONCLUSION： Amlodipine plus telmisartan can improve 24 h microalbuminuria of subjects with hypertension and diabetes, hy- pertension and diabetes 24 h trace urine protein content to good effect. However, because of the lower methodological quality literature, it is still necessary to need a large sample, and long-term adverse reactions follow-up.